Sanofi Partners with EVOQ Therapeutics to Advance NanoDisc-Based Autoimmune Therapies

EVOQ Therapeutics and Sanofi announced a Collaboration and License Agreement on October 16, 2025, to develop therapies for autoimmune diseases using EVOQ's proprietary NanoDisc technology267.

Sanofi will lead global development and commercialization, while EVOQ is eligible to receive over $500 million in upfront, preclinical, development, and sales milestone payments, plus tiered royalties on product sales267.

The NanoDisc platform aims to restore immune tolerance—a root cause of autoimmune diseases—potentially offering curative therapies for conditions like celiac disease, type 1 diabetes, MOG antibody disease, rheumatoid arthritis, and lupus267.

Sources:

2. https://www.biospace.com/press-releases/evoq-therapeutics-announces-collaboration-and-license-agreement-with-sanofi

6. https://www.nasdaq.com/articles/evoq-enters-collaboration-and-license-agreement-sanofi

7. https://www.stocktitan.net/news/SNY/evoq-therapeutics-announces-collaboration-and-license-agreement-with-kmp9okchs6ls.html